Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.95 |
| ▸ | ACVRL1 | P37023 | 12/20 | 0.95 |
| ▸ | RET | P07949 | 5/20 | 0.60 |
| ▸ | ROS1 | P08922 | 5/20 | 0.60 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.56 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 8/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469137 | 1.00 | NTRK1 (0.95) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL441529 | 0.97 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL439931 | 0.97 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL10182283 | 0.92 | NTRK1 (0.95) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL438680 | 0.91 | NTRK1 (0.88) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL439929 | 0.89 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL438653 | 0.89 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL438638 | 0.87 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL439725 | 0.87 | NTRK1 (1.00) | NTRK1ACVRL1RETROS1MET | |
| SCHEMBL438684 | 0.84 | NTRK1 (0.88) | NTRK1ACVRL1RETROS1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | NTRK1 65/4885ACVRL1 592/4885RET 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.